Clinical trial
ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic…
NCT00081042 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00081042 |
|---|---|
| Title | ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma |
| Official title | An Open-Label, Multicenter, Phase II Trial of ABI-007 (A Cremophor® -Free, Protein Stabilized, Nanoparticle Paclitaxel) in Previously Treated Patients With Metastatic Melanoma |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Drug |
| Interventions | paclitaxel albumin-stabilized nanoparticle formulation |
| Start date | Feb 1, 2004 |
| Completion | Jan 1, 2010 |
| First posted | Apr 8, 2004 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: